ONCY
Price:
$0.97
Market Cap:
$107.35M
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgar...[Read more]
Industry
Biotechnology
IPO Date
2001-10-05
Stock Exchange
NASDAQ
Ticker
ONCY
According to Oncolytics Biotech Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.88. This represents a change of -13.77% compared to the average of -4.50 of the last 4 quarters.
The mean historical PE Ratio of Oncolytics Biotech Inc. over the last ten years is -3.88. The current -3.88 PE Ratio has changed 9.91% with respect to the historical average. Over the past ten years (40 quarters), ONCY's PE Ratio was at its highest in in the March 2020 quarter at 43.53. The PE Ratio was at its lowest in in the March 2021 quarter at -9.24.
Average
-3.88
Median
-3.32
Minimum
-6.26
Maximum
-2.24
Discovering the peaks and valleys of Oncolytics Biotech Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 166.70%
Maximum Annual PE Ratio = -2.24
Minimum Annual Increase = -61.12%
Minimum Annual PE Ratio = -6.26
Year | PE Ratio | Change |
---|---|---|
2023 | -4.26 | -17.43% |
2022 | -5.16 | 44.28% |
2021 | -3.57 | -42.93% |
2020 | -6.26 | 108.69% |
2019 | -3.00 | 29.27% |
2018 | -2.32 | -61.12% |
2017 | -5.97 | 166.70% |
2016 | -2.24 | -27.04% |
2015 | -3.07 | 5.57% |
2014 | -2.91 | -50.33% |
The current PE Ratio of Oncolytics Biotech Inc. (ONCY) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-4.33
5-year avg
-4.45
10-year avg
-3.88
Oncolytics Biotech Inc.’s PE Ratio is less than scPharmaceuticals Inc. (-1.96), less than Milestone Pharmaceuticals Inc. (-2.86), greater than Seres Therapeutics, Inc. (-5.75), less than aTyr Pharma, Inc. (-2.33), greater than DiaMedica Therapeutics Inc. (-10.36), less than Inhibikase Therapeutics, Inc. (-1.34), less than X4 Pharmaceuticals, Inc. (0), greater than Galera Therapeutics, Inc. (-6.95), less than Terns Pharmaceuticals, Inc. (-0.08), greater than Day One Biopharmaceuticals, Inc. (-5.12), greater than HOOKIPA Pharma Inc. (-14.52), less than CureVac N.V. (-0.55), less than Reata Pharmaceuticals, Inc. (5.83), greater than Krystal Biotech, Inc. (-20.07), less than Vir Biotechnology, Inc. (86.92), less than Propanc Biopharma, Inc. (-1.89), less than null (-0.06),
Company | PE Ratio | Market cap |
---|---|---|
-1.96 | $169.14M | |
-2.86 | $98.66M | |
-5.75 | $163.91M | |
-2.33 | $131.12M | |
-10.36 | $224.92M | |
-1.34 | $198.89M | |
0 | $98.92M | |
-6.95 | $1.63M | |
-0.08 | $492.65M | |
-5.12 | $1.28B | |
-14.52 | $18.30M | |
-0.55 | $670.67M | |
5.83 | $6.57B | |
-20.07 | $4.56B | |
86.92 | $1.02B | |
-1.89 | $157.98K | |
-0.06 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncolytics Biotech Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncolytics Biotech Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oncolytics Biotech Inc.'s PE Ratio?
How is the PE Ratio calculated for Oncolytics Biotech Inc. (ONCY)?
What is the highest PE Ratio for Oncolytics Biotech Inc. (ONCY)?
What is the 3-year average PE Ratio for Oncolytics Biotech Inc. (ONCY)?
What is the 5-year average PE Ratio for Oncolytics Biotech Inc. (ONCY)?
How does the current PE Ratio for Oncolytics Biotech Inc. (ONCY) compare to its historical average?